Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).

被引：0

作者：

Barthelemy, Philippe

Loriot, Yohann

Voog, Eric

Eymard, Jean Christophe

Ravaud, Alain

Flechon, Aude

Jaillon, Christine Abraham

Chasseray, Matthieu

Lorgis, Veronique

Hilgers, Werner

Gobert, AurElien

Le Moulec, Sylvestre

Simon, Camille

Nicolas, Emanuel

Escande, Anne

Pouessel, Damien

Josse, Constant

Solbes, Marie-Noelle

Lambert, Prisca

Thibault, Constance

机构：

[1] Inst Cancerol Strasbourg Europe, Strasbourg, France

[2] Gustave Roussy, Villejuif, France

[3] Clin Victor Hugo Ctr Jean Bernard, Le Mans, France

[4] Inst Cancerol Jean Godinot, Reims, France

[5] Bordeaux Univ, Bordeaux Univ Hosp, Bordeaux, France

[6] Ctr Leon Berard, Lyon, France

[7] Foch Hosp, Suresnes, France

[8] Ctr Finisterien Radiotherapie & Oncol Clin Pasteu, Brest, France

[9] Inst Cancerol Bourgogne, Dijon, France

[10] Avignon Provence Canc Inst, Avignon, France

[11] St Gregoire Hosp, St Gregoire, France

[12] Clin Marzet, Pau, France

[13] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France

[14] Univ Hosp Nimes, Nimes, France

[15] Clin Ste Anne, Strasbourg, France

[16] Inst Claudius Regaud IUCT Oncopole, Toulouse, France

[17] eXYSTAT, Malakoff, France

[18] Merck Sante SAS, Lyon, France

[19] Pfizer Oncol, Paris, France

[20] Univ Paris Cite, Hop Europeen Georges Pompidou, AP HP Ctr, Inst Canc Paris CARPEM, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

471

引用

页数：1

共 50 条

[31] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.
Powles, Thomas
Petrylak, Daniel P.
Park, Se Hoon
Sridhar, Srikala S.
Caserta, Claudia
Vuillemin, Antoine Thiery
Lee, Hyo Jin
Bellmunt, Joaquim
Yamamoto, Yoshiaki
Aragon-Ching, Jeanny B.
Huang, Bo
Ching, Keith A.
Davis, Craig B.
Di Pietro, Alessandra
Loriot, Yohann
Grivas, Petros
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[32] Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in the US.
Moon, Helen H.
Kearney, Mairead
Mahmoudpour, Seyed Hamidreza
Ike, Chiemeka
Morris, Valerie A.
Rava, Andrew
Kim, Sonia
Sun, Haiyan
Boyd, Marley
Rey, Gabriel Gomez
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 605 - 605
[33] Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study
Miyake, Makito
Shimizu, Takuto
Oda, Yuki
Tachibana, Akira
Ohmori, Chihiro
Itami, Yoshitaka
Kiba, Keisuke
Tomioka, Atsushi
Yamamoto, Hiroaki
Ohnishi, Kenta
Nishimura, Nobutaka
Hori, Shunta
Morizawa, Yosuke
Gotoh, Daisuke
Nakai, Yasushi
Torimoto, Kazumasa
Fujii, Tomomi
Tanaka, Nobumichi
Fujimoto, Kiyohide
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (03) : 253 - 262
[34] Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study.
Grivas, Petros
Barata, Pedro C.
Moon, Helen H.
Gupta, Shilpa
Hutson, Thomas E.
Sternberg, Cora N.
Brown, Jason
Dave, Vaidehi
Downey, Chad
Shillington, Alicia C.
Katzenstein, Howard
Kirker, Melissa
Hanson, Sarah
Liu, Frank X.
Morris, Valerie A.
Bhanegaonkar, Abhijeet
Sonpavde, Guru P.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 697 - 697
[35] Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC).
Moon, Helen H.
Aragon-Ching, Jeanny B.
Thompson, Allison
Abraham, Anup
Vlahiotis, Anna
Ike, Chiemeka
Benjumea, Darrin
Shao, Anran
Sun, Haiyan
Kearney, Mairead
Gharibian, Norbek
Hanson, Sarah
Li, Benjamin
Kirker, Melissa
Grivas, Petros
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] SPADE: Design of a real-world observational study of avelumab first-line maintenance (1LM) in advanced urothelial carcinoma in the Asia-Pacific region
Oliveira, Niara
Su, Po Jung
Park, Se Hoon
Tsai, Yu Chieh
Kim, Miso
Wu, Wen Jeng
Gao, Seasea
Shin, Sang Joon
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 97 - 97
[37] Real-world prescribing patterns for first-line and maintenance treatment of patients with advanced urothelial cancer (UC)
Inderjeeth, Andrisha-Jade
O'haire, Sophie
Gibbs, Peter
Wong, Lih-Ming
Zhang, Alison
Manohar, Paul
James, Lynam
Sengupta, Shomik
Wong, Shirley
Weickhardt, Andrew
Tran, Ben
Conduit, Ciara
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 95 - 95
[38] Real-world trends in first-line checkpoint inhibitor use (CPI) in advanced urothelial cell carcinoma (aUC).
Parikh, Ravi Bharat
Galsky, Matt D.
Baxi, Shrujal S.
Adamson, Blythe J. S.
Cohen, Aaron Benjamin
Feld, Emily
Christodouleas, John Paul
Ben Boursi, Shimon
Meropol, Neal J.
Mamtani, Ronac
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[39] Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland
Critchlow, Simone
Bullement, Ash
Crabb, Simon
Jones, Robert
Christoforou, Katerina
Amin, Amerah
Xiao, Ying
Kapetanakis, Venediktos
Benedict, Agnes
Chang, Jane
Kearney, Mairead
Eccleston, Anthony
FUTURE ONCOLOGY, 2024, 20 (08) : 459 - 470
[40] First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.
D'Angelo, Sandra P.
Russell, Jeffrey
Hassel, Jessica Cecile
Lebbe, Celeste
Chmielowski, Bartosz
Rabinowits, Guilherme
Terheyden, Patrick
Brownell, Isaac
Zwiener, Isabella
Bajars, Marcis
Hennessy, Meliessa
Kaufman, Howard
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →